U.K. Clinical/Cost Effectiveness Reviews Will Delay Drug Launches - ABPI
Executive Summary
The U.K. government's proposed requirements for submission of new product data to the National Institute of Clinical Excellence would lead to inappropriate delays in drug launches, the Association of the British Pharmaceutical Industry maintains.